Parenteral administration of recombinant hematopoietic growth factors has been sporadically associated with cutaneous complications, including injection site reactions in humans and nonhuman primates. In this study, subcutaneous injection sites were evaluated from 12 cynomolgus monkeys administered a recombinant human interleukin-3 (rhIL-3) at dose levels of 0, 70, or 700 μg/kg daily for 18 days. Monkeys administered rhIL-3 developed small (0.5-1-cm-diameter), firm nodules at the subcutaneous injection sites. Histologically, these nodules from 4 of 8 rhIL-3-treated monkeys contained trilineage extramedullary hematopoiesis (EMH) represented by precursors of myeloid, erythroid, and megakaryocytic series cells. The lineage of hematopoietic cells was confirmed by histochemical and immunohistochemical methods. Hematopoietic cells of myeloid and megakaryocytic lineages were more common than erythroid cells. Of myeloid cells, immature eosinophils were more common, which usually formed small sheets or clusters in the panniculus and deep dermis. This report describes, for the first time, the occurrence of cutaneous EMH at the injection sites of recombinant hematopoietic growth factors, which should be differentiated from inflammation. We believe the cutaneous EMH was the exaggerated pharmacologic effect of rhIL-3.
Biesma B., Vellenga E., Willemse PHB, and de Vries EGE (1992). Effects of hematopoietic growth factors on chemotherapy-induced myelosuppression. Critic. Rev. Oncol./Hematol. 13: 107-134.
2.
Brough AJ, Jones D., and Page RH (1967). Dermal erythropoiesis in neonatal infants: A manifestation of intra-uterine viral disease. Pediatrics140: 627-635.
3.
D'Hondt V., Weynants P., Humblet Y., Guillaume T., Canon J., Beauduin M., Duprez P., Longueville J., Mull R., Chatelain C., and Symann M. (1993). Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase 1b study. J. Clin. Oncol . 11: 2063-2071.
4.
Dreicer R., Schiller JH, and Carbone PP (1989). Granulocyte-macrophage colony-stimulating factor and vasculitis. Ann. Intern. Med. 111: 91-92.
5.
Ema H., Suda T., Nagayoshi K., Miura Y., Civin CI, and Nakauchi H. (1990). Target cells for granulocyte-colony stimulating factor, in-MH; ++++ = marked EMH. terleukin-3 and interleukin-5 in differentiation pathways of neutrophils and eosinophils. Blood76: 1956-1961.
6.
Farmer K., Kurzrock R., Gutterman J., and Duvic M. (1990). Necrotizing vasculitis at GM-CSF injection sites . Arch. Dermatol. 126: 1243-1244.
7.
Galli SJ and Lichtenstein LM (1988). Biology of basophils and mast cells. In: Allergy: Principles and Practice, RE Middleton Jr, CE Reed, EF Ellis, and NF Adkinson Jr (eds). Mosby, St Louis, p. 106.
8.
Hoffman R. (1993). Interleukin-3: A potentially useful agent for treating chemotherapy-related thrombocytopenia. J. Clin. Oncol . 11: 2057-2060.
9.
Horn TD, Burke PJ, Karp JE, and Hood JF (1991). Intravenous administration of recombinant human granulocyte macrophage-colony stimulating factor causes a cutaneous eruption . Arch. Dermatol. 127: 49-52.
10.
Huhn RD, Yurkow EJ, Kuhn JG, Clarke L., Gunn H., Resta D., Shah R., Myers LA, and Seibold JR (1995). Pharmacodynamics of daily subcutaneous administration of recombinant human interleukin-3 in normal volunteers. Clin. Pharmacol. Ther. 57: 32-41.
11.
Johnson ML and Grimwood RE (1994). Leukocyte colony stimulating factors: A review of associated neutrophilic dermatoses and vasculitides. Arch. Dermatol. 30: 77-81.
12.
Keller P. and Smalling R. (1993). Granulocyte colony stimulating factor: Animal studies for risk assessment. In: International Review of Experimental Pathology, GW Richter, K Solez, and B Ryffel (eds). Academic Press, San Diego, California, pp. 173-189.
13.
Khan K., Fouant M., Mckearn J., Alden C., and Smith P. (1993). Evaluation of recombinant human IL-3 (rhIL-3) and a synthetic IL-3 mimetic, SC-55494, in the cynomolgus monkey. Vet. Pathol. 30: 458 (abstract 121).
14.
Kirschenbaum AS, Goff JP, Dreskin SC, Irani A., Schwartz LB, and Metcalfe DD (1989). IL-3 dependent growth of basophil-like cells and mastlike cells from human bone marrow. J. Immunol. 142: 2424-2429.
15.
Kuo T., Uhlemann J., and Reinhard E. (1976). Cutaneous extramedullary hematopoiesis. Arch. Dermatol. 112: 1302-1303.
16.
Lieschke GJ and Burgess AW (1992). Granulocyte-colony stimulating factor and granulocyte-macrophage-colony stimulating factor. N . Eng. J. Med. 327: 28-35.
17.
Lindemann A. and Mertelsmann R. (1993). Interleukin-3: Structure and function. Cancer Invest. 11: 609-623.
18.
Lopez AF, Dyson PG, To LB, Elliot MJ, Milton SE, Russell JA, Juttner CA, Yang Y., Clark SC, and Vadas MA (1988). Recombinant human interleukin-3 stimulation of hematopoiesis in human: Loss of responsiveness with differentiation in the neutrophilic myeloid series. Blood72: 1797-1804.
19.
Mayer P., Valent P., Schmidt G., Liehl E., and Bettelheim P. (1989). The in vivo effects of recombinant interleukin-3: Demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates. Blood74: 613-621.
20.
Mizoguchi M. , Kawa Y., Minami T., Nakayama H., and Mizoguchi H. (1990). Cutaneous extramedullary hematopoiesis in myelofibrosis . J. Am. Acad. Dermatol. 22: 351-355.
21.
Moore MAS (1990). Hematopoietic growth factors in cancer. Cancer65: 836-844.
22.
Oster W., Frisch J., Nicolay U., and Schulz G. (1991). Interleukin-3: Biologic effects and clinical impact . Cancer67: 2712-2717.
23.
Oster W. and Schulz G. (1992). Experiences with interleukin-3: In vitro and in vivo. In: Concise Reviews in Clinical and Experimental Hematology , MJ Murphy Jr (ed). AlphaMed Press, Dayton, Ohio, pp. 61-77.
24.
Popoff L. and Popoff N. (1958). L'hemopoiese cutane eau cours de la vie intra-uterine . Ann. Dermatol. Syph. 85: 157-167.
25.
Redmond J. III, Kantor RS, Auerbach HE, Spiritos MD, and Moore JT (1995). Extramedullary hematopoiesis during therapy with granulocyte colony-stimulating factor. Arch. Pathol. Lab. Med. 118: 1014-1015.
26.
Reiner G., Ronneberger H., and Hintz-Obertreis P. (1993). Comparative toxicity of Escherichia coli and yeast rHIL-3 in cynomolgus and rhesus monkeys. In: International Review of Experimental Pathology, GW Richter, K Solez, and Ryffel B (eds). Academic Press, San Diego, California, pp. 119-148.
27.
Robinson RL and Myers LA (1993). Preclinical safety assessment of recombinant human GM-CSF in rhesus monkeys. In: International Review of Experimental Pathology, GW Richter, K Solez, and Ryffel B (eds). Academic Press, San Diego, California, pp. 149-172.
28.
Ross HJ, Moy LA, Kaplan R., and Figlin RA (1991). Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer68: 441-443.
29.
Sato N., Swada K., Koizumi K., Tarumi T., Leko M., Yasukouchi T., Yamaguchi M., Takahashi TA, Skiguchi S., and Koike T. (1993). In vitro expansion of human peripheral blood CD34+ cells. Blood82: 3600-3609.
30.
Schofield JK , Shun JLK , Cerio R., and Grice K. (1990). Cutaneous extramedullary hematopoiesis with a preponderance of atypical megakaryocytes in myelofibrosis . J. Am. Acad. Dermatol. 22: 334-337.
31.
Sheehan DC and Hrapchak BB (1980). Theory and Practice of Histotechnology: Special Cells and Tissues. Battelle Press, Columbus, Ohio, p. 282.
32.
Tagami H., Tashima M., and Uehara N. (1988). Myelofibrosis with skin lesions. Brit. J. Dermatol. 102: 109-112.
33.
Valent P., Besemer J., Sillaber C., Butterfield JH, Eher R., Majdic O., Kishi K., Klepetko W., Eckersberger F., Lechner K., and Bettelheim P. (1990). Failure to detect IL-3 binding sites on human mast cells. J. Immunol. 145: 3432-3437.
34.
Van Gils CJM , Mulder AH, Van Den Bos C., Burger H., Van Leen RW, and Wagemaker G. (1993). Acute side effects of homologous interleukin-3 in rhesus monkeys. Am. J. Pathol . 143: 1621-1633.
35.
Volc-Platzer B., Vaalent P., Radaszkiewicz T., Mayer P., Bettelheim, and Wolff K. (1991). Recombinant human interleukin-3 induces proliferation of inflammatory cells and keratinocytes in vivo. Lab. Invest . 64: 557-566.
36.
Wagemaker G. , van Gils Fcjm, Burger H., Dorssers LCJ, van Leen RW, Persoon NLM, Wielenga JJ, Heeney JL, and Knol E. (1990). Highly increased production of bone marrow-derived blood cells by administration of homologous interleukin-3 to rhesus monkeys. Blood76 : 2235-2241.
37.
Welte K., Zeidler C., Reiter A., Muller W., Odenwald E., Souza L., and Riehm H. (1990). Differential effects of granulocyte-macrophage-colony stimulating factor and granulocyte-colony stimulating factor in children with severe congenital neutropenia. Blood75: 1056-1063.
38.
Zucker-Franklin D. (1990). Megakaryocyte morphology and function. In: Hematology, JW Williams, E Beutler, AJ Erslev, and MA Lichtman (eds). McGraw-Hill, New York , pp. 1161-1171.
